Similarly, Angelos et al. [11] developed a novel Senza5 CAR-T-cell product, which, by knocking down autologous CD5, showed high specificity and low off-target risks, maintained pathogen responsiveness, and has been utilized in phase I trials for treating R/R CD5-positive T-cell lymphomas. This evidence concerns the gene CD5 and T-cell non-Hodgkin lymphoma.